European Standard Clinical Practice Recommendations - For Non-Hodgkin Lymphoma of Childhood and Adolescence - Version 1.0 - 04.10.2021

Sep 29, 2026

Uploaded by McQueen

European Standard Clinical Practice Recommendations for childhood and adolescence non-Hodgkin lymphoma outline evidence-based guidance for background, diagnostic criteria, staging, and treatment planning. The document grounds recommendations in NHL-BFM 95 and EICNHL EURO LB 2002 trials, registry data, and relevant international study trials. It details diagnostic approaches, processing of tissue and specimens, definitions of organ involvement, and treatment specifics across lymphoblastic lymphoma, mature aggressive B-cell lymphoma/leukemia, and anaplastic large cell lymphoma. It also provides treatment assessments, adverse event summaries, and dose modification recommendations for key drugs.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages45

Reading Time1 h 53 min

AccessFree to download

Background and Rationale

Lymphoblastic Lymphoma

Mature Aggressive B-Cell Lymphoma/Leukemia

Anaplastic Large Cell Lymphoma

Patient Group and Diagnostics

Diagnostic Criteria

Classification of NHL

Diagnostic approach and surgery

Processing of tissue and cell specimens

Initial diagnostics

Definition of organ involvement

Staging

Treatment details

Lymphoblastic lymphoma

Mature aggressive B-cell lymphoma/ leukemia

Anaplastic Large Cell Lymphoma

Assessments during treatment

Summary of known adverse events, treatment recommendation and dose modifications

EUROPEAN STANDARD CLINICAL PRACTICE RECOMMENDATIONS FOR NON-HODGKIN LYMPHOMA OF CHILDHOOD AND ADOLESCENCE VASILIKI TZOTZOLA (YOUNG SIOPE) PAULA PEREZ (YOUNG SIOPE) AND ANDISHE ATTARBASCHI on behalf of the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group Auke Beishuizen (Chair of EICNHL) Karin Mellgren (Co-Chair of EICNHL) Suzanne D. Turner (Co-Chair of EICNHL) Andishe Attarbaschi (Co-Chair of EICNHL and i-BFM NHL Committee Chair) Recommendations are based on: NHL-BFM 95 and EICNHL EURO LB 2002 TRIALS NHL-BFM REGISTRY INTERNATIONAL RITUXIMAB TRIAL for HIGH-RISK MATURE B-NHL (EICNHL, COG) EICNHL ALCL99 TRIAL Version 1.0 , 04.10.2021 The ERN PaedCan received funding by the European Union’s Health Programme (2014-2020), grant agreement nr. 847032. Version 1.0, 8.7.2020 Childhood and adolescent NHL Standard Clinical Practice document TABLE OF CONTENTS Table of contents...................................................................................................................................2 List of abbreviations .............................................................................................................................4 1. Background and Rationale..............................................................................................................6 1.1 Lymphoblastic Lymphoma...................................................................................................7 1.2 Mature Aggressive B-Cell Lymphoma/Leukemia ...............................................................8 1.3 Anaplastic Large Cell Lymphoma ..................................................................................... 12 2. Patient Group and Diagnostics..................................................................................................... 14 2.1 Diagnostic Criteria .............................................................................................................. 14 2.1.1 Classification of NHL ......................................................................................................... 14 2.1.2 Diagnostic approach and surgery ...................................................................................... 15 2.1.3 Processing of tissue and cell specimens ........................................................................... 16 2.1.4 Initial diagnostics ............................................................................................................... 16 2.1.5 Definition of organ involvement ......................................................................................... 17 2.1.6 Staging ............................................................................................................................... 18 3. Treatment details ...........................................................................................................................20 3.1 Lymphoblastic lymphoma ..................................................................................................20 3.2 Mature aggressive B-cell lymphoma/ leukemia ...............................................................22 3.2.1 Therapeutic groups and treatment schemes according to the NHL-BFM concept: ...........22 3.2.2 Therapeutic groups and treatment schemes according to the European Intergroup for Children Non-Hodgkin Lymphoma (EICNHL) concept: ..................................................................25 3.3 Anaplastic Large Cell Lymphoma .....................................................................................28 3.4 Assessments during treatment .........................................................................................29 3.5 Summary of known adverse events, treatment recommendation and dose modifications ......................................................................

FAQs

What evidence sources does the recommendations document rely on?

Recommendations are based on NHL-BFM 95 and EICNHL EURO LB 2002 trials, the NHL-BFM registry, and specific international trials including rituximab for high-risk mature B-NHL and EICNHL ALCL99.

What topics are covered under patient group and diagnostics?

It covers diagnostic criteria, classification of non-Hodgkin lymphoma, diagnostic approach and surgery, processing of tissue and specimens, initial diagnostics, definitions of organ involvement, and staging.

How does the document handle treatment details and safety during therapy?

It provides treatment details by disease subtype, assessments during treatment, and a summary of known adverse events with treatment recommendations and dose modifications for multiple drugs.

Sep 29, 2026

Uploaded by McQueen